TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03974009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calcaneal taping
Description: Calcaneal taping will be given in long sitting position foot out of the edge.BSN Medical Leukotape P Sports Tape (3.8cm×137m,1.5inch× 15yds) on focusing the calcaneus with the aim of choosing dorsiflexion with eversion. First strap of tape will be applied below the medial malleolus,stretch towards lateral malleolus on affected side. Second strap of tape will be applied repetitively placing the first strap,another will be applied to fix the small tapes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham taping
Description: Sham taping will be given to the control group patients.Simple clinical tape will be applied on calcaneus without stretch.It will be applied for 3 days/week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: Balance activities (Forward, backward and sideways walking in between 2 parallel lines;Ball kicking against wall(reducing upper limb support)to raising the distance from the wall, kicking to the fixed target; Obstacle walking and Strengthening exercises (Sit to Stand from several heights of chair, Forward \& backward and sideward stepping onto blocks of several heights. Each acitivity will be given for 5 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Balance activities (Forward, backward and sideways walking in between 2 parallel lines;Ball kicking against wall(reducing upper limb support)to raising the distance from the wall, kicking to the fixed target; Obstacle walking and Strengthening exercises (Sit to Stand from several heights of chair, Forward \& backward and sideward stepping onto blocks of several heights. Each acitivity will be given for 5 minutes.
Study: NCT04182893

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA and Exosome Combined Detection
Description: Through the detection and analysis of blood and alveolar lavage fluid of 300 patients with pulmonary nodules and 100 healthy population, the diagnostic efficacy of ctDNA and exosomes combined detceion will be studied.

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA and Exosome Combined Detection
Description: Through the detection and analysis of blood and alveolar lavage fluid of 300 patients with pulmonary nodules and 100 healthy population, the diagnostic efficacy of ctDNA and exosomes combined detceion will be studied.
Study: NCT00092729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib (MK0663)
Description: Two etoricoxib 60 mg tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: naproxen sodium
Description: Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
Study: NCT01708603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 210 mg brodalumab
Description: 210 mg brodalumab administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 210 mg brodalumab
Description: 210 mg brodalumab administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg brodalumab
Description: 140 mg brodalumab administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ustekinumab
Description: 45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered SC
Study: NCT04412304

Intervention type: DRUG
Intervention: Dose of Tinzaparin or Dalteparin
Description: The patients will be categorised into three groups depending on initial regime of anticoagulants after arrival in the ICU.

Intervention type: DRUG
Intervention: Dose of Tinzaparin or Dalteparin
Description: The patients will be categorised into three groups depending on initial regime of anticoagulants after arrival in the ICU.

Intervention type: DRUG
Intervention: Dose of Tinzaparin or Dalteparin
Description: The patients will be categorised into three groups depending on initial regime of anticoagulants after arrival in the ICU.
Study: NCT04403282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eflornithine Topical
Description: Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Eflornithine Topical
Description: Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
Study: NCT03942731

Intervention type: OTHER
Intervention: Behavioral allergy testing protocol
Description: skin tests followed by drug provocation test and skin retesting between 6 weeks and 6 months
Study: NCT01617213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 200 mg/m2/IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg daily continuously for the first 3 months, then increased to 15 mg daily as long as the patient tolerates the drug.
Study: NCT00313170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection 250 mg \& 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection 250 mg \& 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection 250 mg \& 500 mg
Study: NCT00358488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159797 (10, 15, and 20mcg)
Description: GSK159797 (10, 15, and 20mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: salbutamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol 50mcg
Description: salmeterol 50mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05419440

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic drainage of appendicular abscess
Description: access to caecum and remove any adhesions with surrounding by sharp \& blunt dissection , then access to appendicular abscess by sharp and blunt dissection after complete separation of the appendix from surrounding \& complete drainage of pus \& removal of all necrotic tissue , removal of the remnant appendix , in cases with healthy base of appendix ,we closed the stump with endo-loop , in case with unhealthy base , we closed the stump by suturing by ethibond 2/0 in two layers in case with little edema \& inflammation of caecum ( sutures not cut through ) , in cases with marked edema and inflammation of caecum , we close the site of base by omental patch fixed by taking full thickness sutures in wall of caecum and pass through omental patch , we examine any leak by pressing on caecum and observe any fecal matter comes \& air leak test , in all cases we put large drain at pelvis
Study: NCT04286880

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: Clinically proven cases of Trigger points in masseter muscle will be randomly and equally divided into test group and control group. The selected subjects will be divided into two groups.~Test group will be administered 0.5 ml of PRP solution per trigger point in masseter muscle according to symptoms of patient at baseline (0 week). PRP will be prepared as per methodology mentioned by Okuda et al 2003.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: In control group all the armamentarium and procedure will remain same except that no PRP solution will be delivered. Only dry needling will be performed on the baseline.
Study: NCT02818543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYC-30937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYC-30937
Study: NCT02324543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV on days 4 and 11 of a 21 day cycle
Study: NCT01745003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is based on the application of a weak direct current to the scalp that flows between two relatively large electrodes-anode and cathode. We will be using this device to investigate fibromyalgia.
Study: NCT05896345

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SWL
Description: Shockwave Lithotripsy (SWL) For Paediatrics Radiolucent Renal Stone

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: SWL and ODT
Description: Shockwave Lithotripsy (SWL) and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone
Study: NCT03840876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WEI NASAL JET (WNJ)
Description: Jet ventilation was achieved with WEI NASAL JET (WNJ) connected to a manual jet ventilator (Driving pressure: 40 psi, fraction of inspired oxygen: 100% O2, Respiratory rate: 25/min, I/E ratio: 40%)
Study: NCT02355301

Intervention type: PROCEDURE
Intervention: orthopedic
Description: Compare the type of treatment chosen by the orthopedist with a functional assessment (ICF-WHO model)
Study: NCT03913754

Intervention type: OTHER
Intervention: Psycho-social consequences of lupus erythematosus
Description: It will be necessary to take into account the psychosocial experience of the disease \[47\] and to allow a narrative exploration of this experience and its psycho-social consequences both for the patients and their spouses (ie the experiential dimension of the disease in connection with the life trajectory, the life of a couple, elaborate representations concerning the disease). The purpose of this approach is not only to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inclusion in the socio-cultural condition of the patients, but also to allow an analysis of the inscription. of the disease in the relationship and its implications (relational, affective, sexual) and its impact on the possibilities of social participation.

Intervention type: OTHER
Intervention: Psycho-social consequences of lupus erythematosus
Description: It will be necessary to take into account the psychosocial experience of the disease \[47\] and to allow a narrative exploration of this experience and its psycho-social consequences both for the patients and their spouses (ie the experiential dimension of the disease in connection with the life trajectory, the life of a couple, elaborate representations concerning the disease). The purpose of this approach is not only to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inclusion in the socio-cultural condition of the patients, but also to allow an analysis of the inscription. of the disease in the relationship and its implications (relational, affective, sexual) and its impact on the possibilities of social participation.
Study: NCT01737775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragmatic amplitude measurement
Description: Diaphragmatic amplitude is measured by M Mode ultrasonography the day before and after surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragmatic amplitude measurement
Description: Diaphragmatic amplitude is measured by M Mode ultrasonography the day before and after surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragmatic amplitude measurement
Description: Diaphragmatic amplitude is measured by M Mode ultrasonography the day before and after surgery
Study: NCT01902108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Local infiltration before wound incision with 20 ml of Bupivacaine 0.25 % alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine 150μg locally infiltrated with 20 ml of bupivacaine 0.25 % before wound incision
Study: NCT02801175

Intervention type: PROCEDURE
Intervention: Pulmonary vein isolation

Intervention type: PROCEDURE
Intervention: Pulmonary vein isolation
Study: NCT00909272

Intervention type: PROCEDURE
Intervention: Lumbar medial branch block
Description: The ultrasound probe will be placed perpendicular to skin along the midline of lumbar spinous process on longitudinal view first to count the lumbar level. The midpoint of each lumbar level will be marked on the longitudinal view and then will be rotated ninety degrees counter clockwise to axial view to locate the facet joint and the transverse process of lumbar spine. A #22 gauge 10cm long Quincke spinal needle will be inserted to the target area using in plane approach on the axial view. Then the probe will be rotated ninety degrees clockwise to longitudinal view to ensure needle tip is placed on the cephalad aspect of the transverse process. It will then be immediately confirmed by C-arm fluoroscopy on oblique view.

Intervention type: PROCEDURE
Intervention: Ultrasound landmarks
Description: The target point is the superior medial aspect of transverse process of lumbar spine from L3 to S1. A #22 gauge 10cm long Quincke spinal needle will be use for needle placement. Needle placement will be visualized with ultrasound. Practice on cadavers with 3 different operators and see if results are reproducible. Verify with fluoroscopy.
Study: NCT02790229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anti-gravity treadmill (alter G®)
Description: Patients in the experimental arm will be treated with manual lymphatic drainage, cryotherapy and a fixed protocol of training in an anti-gravity treadmill (alter G®). The protocol is designed parallel to standard physiotherapy with a frequency of two to three times a week with duration of about 20 minutes for six weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: standardized physiotherapy
Description: Patients in the control arm will be treated with manual lymphatic drainage, cryotherapy and 20 minutes of physiotherapy two to three times a week for six weeks. Physiotherapy will be done according to a standardized protocol.
Study: NCT03322800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral
Study: NCT03563144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin HCl
Description: Albumin-binding prodrug of doxorubicin HCl

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-021
Description: Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
Study: NCT03731013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Description: Participants randomized in the Mediterranean diet group without physical activity will be instructed and supported towards adhering to principles of the Mediterranean diet, without changes in physical activity habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Description: Participants randomized in the group physical activity without Mediterranean diet will participate in a structured, supervised PA program to achieve 150 min of moderate PA per week, without changes in dietary habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet and physical activity
Description: The combination group (MedDiet + PA) will receive the combination of both interventions.
Study: NCT00275613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
Study: NCT03322800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
Study: NCT00896259

Intervention type: OTHER
Intervention: home based exercise and education program
Description: Individual assessment with physiotherapist with educational information, exercise instruction and prescription provided. Instructed to perform home exercises and walking for 12 weeks. Will be individually tailored to participants, bi-monthly phone calls will be used to monitor and facilitate exercise and walking progression .
Study: NCT03322800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
Study: NCT01155141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar Gel
Description: Patients were treated with 40 units subcutaneously (SC) weekly for 2 weeks, then dose increased to 80 units SC weekly for 2 weeks followed by 80 units SC twice weekly to complete 16 weeks of therapy.
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G1 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G2 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
Study: NCT00847028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucose 10%
Description: 2 minutes prior to the venipuncture, a 10% glucose concentration was administered orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% glucose
Description: 2 minutes prior to the venipuncture, a 20% glucose concentration was administered orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucose 30%
Description: 2 minutes prior to the venipuncture, a 30% glucose concentration was administered orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sterile water
Description: 2 minutes prior to the venipuncture, sterile water was administered orally
Study: NCT02948894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device
Description: an oral appliance (a dental device) for obstructive sleep apnea

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mandibular advancement device
Description: an oral appliance (a dental device) for obstructive sleep apnea
Study: NCT03200821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT
Description: 250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 µg/m\^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
Study: NCT03572296

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol and fibre
Description: Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fibre
Description: Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.